Can you take Wegovy with a normal BMI?

Why does Wegovy have a BMI threshold in the first place?

The BMI thresholds in Wegovy's UK licence are not arbitrary. They reflect the population studied in the clinical trials that underpinned approval, and the risk-benefit calculation the MHRA conducted before licensing the medicine. Semaglutide at 2.4 mg produces meaningful average weight loss (the STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average body-weight reduction over 68 weeks) but that benefit was demonstrated in adults with obesity or overweight plus a weight-related condition. At a normal BMI, the balance of risk and benefit shifts considerably. Side effects including nausea, vomiting and gastrointestinal discomfort are common, particularly in the first weeks of treatment, and those effects are harder to justify when the clinical need for significant weight loss is absent.

The MHRA has been explicit on this point. Its public guidance on GLP-1 medicines states these treatments are not assessed for quick or cosmetic weight loss. A prescriber working within UK law and professional standards cannot issue a prescription for Wegovy to someone with a normal BMI simply because they want to lose a small amount of weight. That is not a gatekeeping quirk — it is the licence.

If you are uncertain where your BMI sits, the NHS BMI calculator is a straightforward starting point before you consider any clinical route.

What if your BMI is just above the normal range, does 27 qualify?

This is where the picture becomes more nuanced, and it is one of the questions our prescribers at nume hear regularly. A BMI of 27 to 29.9 is classified as overweight rather than obese, and Wegovy's UK licence does cover this range, but only when at least one weight-related health condition is present. Conditions that can count include type 2 diabetes, prediabetes, hypertension, high cholesterol, obstructive sleep apnoea and certain cardiovascular conditions.

So if your BMI is 28 and you have well-documented high blood pressure, you may meet the licensed criteria. If your BMI is 28 with no qualifying comorbidity, you do not. The distinction matters enormously in practice. You can read more about exactly how the BMI thresholds work in our guide to BMI requirements for Wegovy, which sets out the threshold detail in full.

It is also worth knowing that for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, clinical guidance in the UK supports applying thresholds that are 2.5 kg/m² lower. A prescriber takes your full clinical picture into account, not just a single number. Understanding how BMI 30 is assessed for Wegovy can help clarify where the core threshold sits and why.

Is there any legitimate route to Wegovy at a normal BMI in the UK?

Straightforwardly: no, not through a regulated pharmacy prescribing within the medicine's licensed indication. Wegovy at a normal BMI sits outside the authorised use. Prescribing it in that context would be off-label, and UK regulatory guidance and professional standards make clear that regulated services do not offer GLP-1 medicines for cosmetic weight loss or to people who do not meet the eligibility criteria.

If you have seen sellers online offering semaglutide without a clinical assessment, that is a serious red flag. The MHRA has repeatedly warned about counterfeit and illegally traded weight-loss medicines, some seized fake pens have contained insulin, a potentially life-threatening substitution. Any service offering these medicines without proper clinical review is not operating within UK law.

For people wondering whether a different medication might apply at a lower BMI, the semaglutide and normal BMI question covers the landscape for semaglutide products more broadly, since the same general principles apply across the GLP-1 class. The cost of Wegovy as a private treatment is a separate consideration that only becomes relevant once eligibility is established.

The Wegovy tablet (oral semaglutide, approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK) carries the same BMI thresholds as the injection. A normal BMI does not open a different door via the tablet form. Storage is simpler (no refrigeration needed; the tablet fits easily in a handbag or gym bag), but the eligibility criteria are the same.

What should you do if you are close to the threshold but not quite there?

If your BMI sits just below 27, or you are at 27 but unsure whether a health condition qualifies, the most useful step is a proper clinical assessment. Self-calculating on a website only takes you so far. A prescriber considers your weight history, any underlying conditions, your overall health profile and the clinical guidance together, there is genuine nuance in that process that a BMI chart alone cannot capture.

For context on what the lower end of the overweight BMI range means in practice, the page on BMI 25 and Wegovy eligibility sets out the position honestly. And if you want to see the full picture of what Wegovy involves as a treatment, our Wegovy overview covers the medicine, the trial evidence, the dosing schedule and the process in one place.

If you think you may be eligible, or you simply want a clinician to look at your specific situation, a free consultation with one of our prescribers is a sensible first step. There is no obligation. A real clinician reviews every consultation the same day (not software) and will tell you plainly whether treatment is clinically suitable. You can also explore our broader weight-loss treatment options if you are weighing up which approach fits best.